Angelicin potentiates TRAIL‐induced apoptosis in renal carcinoma Caki cells through activation of caspase 3 and down‐regulation of c‐FLIP expression

Publisher： John Wiley & Sons Inc

E-ISSN： 1098-2299|79|1|3-10

ISSN： 0272-4391

Source： DRUG DEVELOPMENT RESEARCH, Vol.79, Iss.1, 2018-02, pp. : 3-10

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

AbstractPreclinical Research Development

Angelicin is a furocoumarin derived from Psoralea corylifolia L. fruit that has anti‐inflammatory and anti‐tumor activity. In the present study, the effect of angelicin in enhancing tumor necrosis factor‐related apoptosis‐inducing ligand (TRAIL)‐induced apoptotic cell death was studied in Caki (renal carcinoma) cells. Angelicin alone and TRAIL alone had no effect on apoptosis, but in combination these compounds markedly induced apoptosis in the cancer cell lines while not inducing apoptosis in normal cells. The combination treatment induced accumulation of the sub‐G1 population, DNA fragmentation, and activated caspase 3 activity in Caki cells, induced down‐regulation of c‐FLIP expression post‐translationally, and over‐expression of c‐FLIP markedly blocked apoptosis induced by combined treatment with angelicin plus TRAIL. This study provides evidence that angelicin might be a TRAIL sensitizer.